* Rigel Pharmaceuticals Inc RIGL.OQ RIGL.O is expected
to show
a rise in quarterly revenue when it reports results on March
7.
* The South San Francisco California-based company is
expected to
report a 37.0% increase in revenue to $27.968 million from
$20.41 million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. The company's guidance on
January 9 2023, for the period ended December 31, was for
revenue of $51.300 million.
* Refinitiv's mean analyst estimate for Rigel
Pharmaceuticals Inc
is for a loss of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2, above its last closing price
of $1.62.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.13 -0.13 -0.11 Beat 18.2
Jun. 30 2022 -0.13 -0.12 -0.08 Beat 34.8
Mar. 31 2022 -0.14 -0.14 -0.16 Missed -16.5
Dec. 31 2021 -0.13 -0.13 -0.13 Met -1.8
Sep. -0.09 -0.10 -0.12 Missed -20.4
30 2021
Jun. 30 2021 -0.11 -0.11 -0.08 Beat 30
Mar. 31 2021 0.04 0.00 0.22 Beat 4,454.
9
Dec. 31 2020 -0.11 -0.11 -0.11 Met 3.2
This summary was machine generated March 3 at 23:10 GMT. All
figures in US dollars unless otherwise stated